- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04131504
Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION) (ENvISION)
A Multi-Center, Prospective Study to Discover a Companion Diagnostic for Biologics Targeting TNF
Crohn's disease and ulcerative colitis affect about 1.6 to 3 million people in the United States with many of those being young children and adolescents. Physicians need better ways to inform decisions on therapy selection and recognize ongoing intestinal injury while on treatment.
The main reason for this research study is to see if a blood test or stool test, which measures specific proteins, taken just before starting a new treatment for Crohn's disease can predict a patient's ability to achieve complete intestinal healing. The investigators also want to see if the intensity of gut inflammation can be detected by measuring a separate set of proteins in the blood.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Despite the heterogeneity of CD phenotypes and a potentially aggressive course of inadequately treated CD, treatment selection for newly diagnosed patients is currently based on clinical factors which do not define CD sub-types. Now, with additional biologic therapies for CD, there is a critical need for individual biochemical analysis both pre-treatment, and following induction to assess the probability of durable remission. These data will inform decisions on continued dosing of the current biologic, or whether addition of combination therapy or switching to a therapy with an alternative mechanism of action will be more beneficial.
The Food & Drug Administration (FDA) defines a companion diagnostic as a device that can identify patients most likely to benefit from a therapy or a device to monitor response with the purpose to adjust the treatment to achieve improved effectiveness.Our global aim is to develop a companion diagnostic (peripheral blood panel) that accurately predicts the probability of deep remission (clinical remission with MH) to anti-TNF and a protein (blood) biomarker panel that reproducibly distinguishes endoscopic MH from active (ulcerated) intestinal inflammation in patients with CD.
The long-term strategy is to utilize the "low-risk" anti-TNF specific module (protein panel) to personalize CD therapy. With the addition of new biologics for CD, patients with a low-risk inflammatory profile would not only be expected to achieve MH but also predicted to respond to treatment escalation strategies while avoiding or stopping the drug (if drug exposure is optimized) sooner in patients in which the protein profile predicts a low probability of deep remission with anti-TNF. As additional therapies are approved for pediatric CD, the priority would be to avoid anti-TNF in patients with a "high-risk" protein profile and specifically select therapies that target the patient's individual inflammatory signature. Additionally, the investigators expect the protein profile of patients failing to achieve deep remission to provide further insight into molecular mechanisms contributing to the continued inflammation and thereby directing the next therapeutic option.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Connecticut
-
Hartford, Connecticut, United States, 06016
- Connecticut Children's Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Potential IBD participants will be recruited through the Division of Gastroenterology at each participating site.
Healthy volunteers will be recruited from through direct advertising methods approved by the IRB and formal local databases intended for recruitment.
Description
Phase I - Cross-sectional Study (CD and Suspected IBD)
Inclusion Criteria:
- Age criteria: > 1 year to < 22 years of age
- Diagnosis of Crohn's disease, anti-TNF naïve, and colonoscopy scheduled OR
- Clinical suspicion for IBD (treatment naïve) and colonoscopy scheduled
- Permission of parent/guardian and assent or consent of research participant
Exclusion Criteria:
- Any prior treatment with an anti-TNF, such as infliximab, adalimumab, certolizumab or golimumab
- Known diagnosis of ulcerative colitis (UC) or inflammatory bowel disease-unspecified (IBD-U)
- Active or prior evidence of internal (abdominal/pelvic) penetrating fistula(e)
- Active intra-abdominal abscess or perianal abscess
- Active Clostridium difficile infection or other known enteric infection in last 2 weeks
- Current ileostomy or colostomy, extensive small bowel resection, ileoanal pouch or short bowel syndrome
- History of autoimmune disease (including autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis)
- Any condition that in the opinion of the PI will prevent the research participant from taking part in this study
Phase I - Cross-sectional Study (healthy volunteers)
Inclusion Criteria:
- Age criteria: > 1 year to < 22 years of age
- Any CCHMC patient
- Permission of parent/guardian and assent or consent of research participant
Exclusion Criteria:
- Known diagnosis of one or more of the following: irritable bowel syndrome, gastroesophageal reflux, constipation, BMI>95% for age, small intestinal bacterial overgrowth (SIBO) or history of intestinal polyps
- Received any antibiotic in the last 30 days or known viral or bacterial illness in the last 30 days
- Any NSAID use in the last 14 days
- History of an autoimmune disease (including diabetes, autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis)
- Any condition that in the opinion of the PI will prevent the research participant from taking part in this study
Phase II - Longitudinal Study of Participants with CD
Inclusion Criteria:
- Age criteria: > 1 year to < 22 years of age
Diagnosis of Crohn's disease with:
- Luminal inflammation (ulcerations in ileum and/or colon visible by ileocolonoscopy) and
- Endoscopic evidence of active Crohn's disease (up to 90 days prior to starting anti-TNF) OR if no colonoscopy within 90 days then fecal calprotectin ≥250 µg/g or fecal lactoferrin >10 µg/g (<90 days from starting anti-TNF)
- Anti-TNF naïve
- Starting infliximab or adalimumab (or either biosimilar)
- Permission of parent/guardian and assent or consent of research participant
Exclusion Criteria:
- Crohn's disease limited to esophagus, stomach, duodenum or jejunum
- Prior treatment with infliximab, adalimumab, certolizumab or golimumab
- Known diagnosis of Ulcerative colitis (UC) or inflammatory bowel disease-unspecified (IBD-U)
- Active or prior evidence of internal (abdominal/pelvic) penetrating fistula(e)
- Active intra-abdominal abscess or perianal abscess
- Active Clostridium difficile infection or other known enteric infection in last 2 weeks
- Current ileostomy or colostomy, extensive small bowel resection, ileoanal pouch or short bowel syndrome
- History of autoimmune disease (including autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis)
- Contraindications to MRI scanning, such as metal implants/non-compatible medical devices or medical conditions
- Any condition that in the opinion of the PI will prevent the research participant from taking part in this study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Phase I - Cross-sectional Study (CD and Suspected IBD)
150 children and young adults who have been previously diagnosed with CD (anti-TNF naïve) or suspected of having IBD (based on clinical symptoms and laboratory testing) who are scheduled for a clinically-indicated colonoscopy are eligible to be enrolled in this cohort.
|
|
Phase I - Cross-sectional Study (healthy volunteers)
20 healthy controls will be enrolled at Cincinnati Children's Hospital only.
Once demographics, past medical/surgical history and biospecimens (blood/stool) are collected, controls will complete participation.
|
|
Phase II - Longitudinal Study of Participants with CD
70 children and young adults who have been diagnosed with CD (anti-TNF naïve) and are scheduled to receive infliximab (or adalimumab) are eligible to be enrolled in this cohort.
|
No standard dosing regimen will be used and the dose will be determined by the treating physician
Other Names:
No standard dosing regimen will be used and the dose will be determined by the treating physician
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sustained Deep Remission
Time Frame: 1 year
|
Sustained Deep Remission, defined as meeting all of the following at 1 year (check all that apply):
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
End of Induction Outcomes: Clinical Response
Time Frame: Week 16
|
Improvement of >17.5 points from baseline wPCDAI and/or Week 16 wPCDAI= <12.5 points
|
Week 16
|
End of Induction Outcomes: Clinical Remission
Time Frame: Week 16
|
wPCDAI <12.5 at Week 16
|
Week 16
|
End of Induction Outcomes: Steroid Free Clinical Remission
Time Frame: Week 16
|
wPCDAI <12.5 and off prednisone by Week 16
|
Week 16
|
End of Induction Outcomes: Fecal Biochemical Response
Time Frame: Week 16
|
Fecal calprotectin improved >50% from baseline stool (+/- 30 days from Week 16)
|
Week 16
|
End of Induction Outcomes: Fecal Biochemical Remission
Time Frame: Week 16
|
Fecal calprotectin <250µg/g at Week 16 (+/- 30 days)
|
Week 16
|
End of Induction Outcomes: Blood CRP Biochemical Remission
Time Frame: Week 16
|
CRP <0.5 mg/dL at Week 16
|
Week 16
|
End of Induction Outcomes: Blood CD64 Biochemical Remission
Time Frame: Week 16
|
nCD64 <4.5 at Week 16
|
Week 16
|
Week 52 Outcomes: Endoscopic Response
Time Frame: 1 year
|
50% reduction in SES-CD score from baseline SES-CD (if performed)
|
1 year
|
Week 52 Outcomes: Endoscopic Remission
Time Frame: 1 year
|
SES-CD <3
|
1 year
|
Week 52 Outcomes: Minimal Endoscopic Activity
Time Frame: 1 year
|
SES-CD <6 with no individual SES-CD subscore >1
|
1 year
|
Week 52 Outcomes: Complete Intestinal Healing
Time Frame: 1 year
|
SES-CD = 0
|
1 year
|
Week 52 Outcomes: Sustained, Steroid-free Clinical Remission
Time Frame: 1 year
|
wPCDAI <12.5 for all visits from weeks 30-52, off prednisone
|
1 year
|
Week 52 Outcomes: Clinical Remission
Time Frame: 1 year
|
wPCDAI <12.5 and off prednisone at last study visit
|
1 year
|
Week 52 Outcomes: Clinical Remission and Endoscopic Response
Time Frame: 1 year
|
wPCDAI <12.5 at week 52 and SES-CD>50% reduction from baseline
|
1 year
|
Week 52 Outcomes: Clinical Remission and Minimal Endoscopic Activity
Time Frame: 1 year
|
wPCDAI <12.5 at week 52 and SES-CD<6 with no individual SES-CD subscore >1
|
1 year
|
Week 52 Outcomes: Treatment Response
Time Frame: 1 year
|
continues on anti-TNF without surgery, hospitalization and off prednisone by week 16
|
1 year
|
Week 52 Outcomes: Transmural ileal healing
Time Frame: 1 year
|
ileum subscore stage 0 (score = 0) or stage 1 (score 1-3)
|
1 year
|
Week 52 Outcomes: Transmural colonic healing
Time Frame: 1 year
|
all segments of colon subscore stage 0 (score=0) or stage 1 (score 1-3)
|
1 year
|
Week 52 Outcomes: Total Bowel Transmural healing
Time Frame: 1 year
|
total ileum and colonic subscore is not greater than stage 1 on either individual score
|
1 year
|
Week 52 Outcomes: Fecal Biochemical Remission
Time Frame: 1 year
|
fecal calprotectin <250 µg/g at week 52
|
1 year
|
Week 52 Outcomes: Deep Fecal Biochemical Remission
Time Frame: 1 year
|
fecal calprotectin <150 µg/g at week 52
|
1 year
|
Week 52 Outcomes: CRP Biochemical Remission
Time Frame: 1 year
|
CRP <0.5 mg/dL at week 52
|
1 year
|
Week 52 Outcomes: CD64 Biochemical Remission
Time Frame: 1 year
|
nCD64 <4.5 at week 52
|
1 year
|
Week 52 Outcomes: PGA Remission
Time Frame: 1 year
|
physician-rated PGA is quiescent and subject is off prednisone
|
1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Phillip Minar, MD, MS, Children's Hospital Medical Center, Cincinnati
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-0730
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn's Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Massachusetts General HospitalAmerican College of GastroenterologyNot yet recruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's EsophagitisUnited States
-
Richard Burt, MDTerminatedCROHN'S DISEASEUnited States
-
Agomab Spain S.L.RecruitingFibrostenotic Crohn's DiseaseUnited States, Italy, Poland, Spain, Denmark, Austria, Canada, Germany
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
-
University Hospital, LilleMinistry of Health, FranceTerminatedCrohn's Disease AggravatedFrance
-
TakedaRecruitingCrohn's Disease (CD)United States, Australia, Israel, Spain, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Lithuania, Poland, Russian Federation, Slovakia, Ukraine, United Kingdom
-
Weill Medical College of Cornell UniversityThe Kenneth Rainin FoundationRecruitingCrohn's Disease (CD)United States
Clinical Trials on Infliximab
-
Onze Lieve Vrouwe GasthuisSanteonUnknown
-
Merck Sharp & Dohme LLCIntegrated Therapeutics GroupTerminatedRheumatoid Arthritis
-
PfizerCompleted
-
Diakonhjemmet HospitalSouth-Eastern Norway Regional Health AuthorityCompletedRheumatoid Arthritis | Crohn's Disease | Ulcerative Colitis | Psoriatic Arthritis | Spondyloarthritis | Psoriasis ChronicNorway
-
NYU Langone HealthWithdrawnInflammatory Bowel Disease
-
Centre hospitalier de l'Université de Montréal...Ottawa Hospital Research Institute; Maisonneuve-Rosemont Hospital; Niagara Health... and other collaboratorsRecruiting
-
PfizerCompletedPsoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic PsoriasisJapan
-
European Organisation for Research and Treatment...CompletedMyelodysplastic SyndromesFrance, Belgium, Netherlands, Czech Republic, Italy, Germany
-
Janssen Research & Development, LLCJanssen Biologics BVCompletedUlcerative ColitisUnited States, France, United Kingdom, Belgium, Switzerland, Israel, Canada, Australia, Netherlands, New Zealand, Austria, Germany, Denmark, Czechia, Argentina
-
BiocadCompletedAnkylosing SpondylitisRussian Federation, Belarus